Spectacles that use SightGlass Vision Diffusion Optics Technology have demonstrated efficacy in slowing the progression of myopia in children,1 based on 24-month interim data from its pivotal clinical trial, known as CYPRESS.
Spectacle lenses using patent-protected SightGlass Vision Diffusion Optics Technology incorporate thousands of microdots that softly scatter light to reduce contrast on the retina – a method intended to reduce myopia progression in children.
An analysis of full-time wearers – children ages six to 10 at initiation, whose parents reported that they did not remove the study spectacles for near vision activities – showed statistically significant improvements between groups using Diffusion Optics Technology lenses and the control. Axial length exhibited a 0.21mm difference, and the spherical equivalent refraction difference was 0.52D.
Study investigators enrolled, randomised, and dispensed the lenses to 256 eligible children across 14 clinical trial sites in the United States and Canada – a geographical distinction compared to most other myopia-related spectacle lens studies. At the time of enrolment, subjects had myopia between -0.75D and -4.50D.
With a mean age of 8.1 years at screening, the CYPRESS cohort is younger than children in other well-known myopia management studies.2,3,4 Given the higher likelihood of spectacles-based interventions for younger children, this study parameter should help build confidence in prescribers and families alike.
- Spectacles with SightGlass Vision Diffusion Optics Technology™ are not approved for sale within the United States.
- GwiazdaJ, Hyman L, Hussein M, et al. A Randomized Clinical Trial of Progressive Addition Lenses versus Single Vision Lenses on the Progression of Myopia in Children. Invest OphthalmolVis Sci. 2003;44(4):1492.
- Walline JJ, GaumeGiannoni A, Sinnott LT, et al. A Randomized Trial of Soft Multifocal Contact Lenses for Myopia Control: Baseline Data and Methods. Optometry and Vision Science. 2017;94(9):856-866.
- Yam JC, Jiang Y, Tang SM, et al. Low-Concentration Atropine for Myopia Progression (LAMP) Study. Ophthalmology. 2019;126(1):113-124.